AU2011202871B2 — Acetylcysteine composition and uses therefor
Assigned to Cumberland Pharmaceuticals Inc · Expires 2014-06-12 · 12y expired
What this patent protects
This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and 5 which are substantially free of metal chelating agents, such as EDTA. Further, this invention relates to methods of making and using the acetylcysteine compositions. The prese…
USPTO Abstract
This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and 5 which are substantially free of metal chelating agents, such as EDTA. Further, this invention relates to methods of making and using the acetylcysteine compositions. The present compositions and methods are designed to improve patient tolerance and compliance, while at the same time io maintaining the stability of the pharmaceutical formulation. The compositions and methods of this invention are useful in the treatment of acetaminophen overdose, acute liver failure, various cancers, methacrylonitrile poisoning, reperfusion injury during is cardio bypass surgery, and radiocontrast-induced nephropathy, and can also be used as a mucolytic agent. 2693404_ 1 (GHMatters) P76914.AU. I 2/oei 1
Drugs covered by this patent
- Acetadote (Acetylcysteine) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.